Adjuvanticity effect of sodium alginate on subcutaneously injected BCG in BALB/c mice

Microbes and Infection

Volumn 11, Issue 2, 2009, Pages 296-301

  Dobakhti, Faramarz ^a   Naghibi, Taraneh ^b   Taghikhani, Mohammad ^c,d   Ajdary, Soheila ^c   Rafinejad, Ali ^b   Bayati, Khosrow ^e   Rafiei, Shahnaz ^b   Rafiee Tehrani, Morteza ^f  

^a ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d TARBIAT MODARES UNIVERSITY   (Iran)

^e IranNajo Pharmaceutical Co   (Iran)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adjuvanticity; Alginate; BCG; Subcutaneous vaccination

Indexed keywords

ALGINIC ACID; BACTERIUM ANTIBODY; BCG VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL COUNT; BAGG ALBINO MOUSE; CELL PROLIFERATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; EXPERIMENTAL INFECTION; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNOGLOBULIN PRODUCTION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALGINATES; ANIMALS; ANTIBODIES, BACTERIAL; BCG VACCINE; COLONY COUNT, MICROBIAL; FEMALE; GLUCURONIC ACID; HEXURONIC ACIDS; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; LUNG; MICE; MICE, INBRED BALB C; TUBERCULOSIS;

BACTERIA (MICROORGANISMS); MUS; MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG;

EID: 61449140003     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2008.12.003     Document Type: Article

References (22)

1. Lindblad E.B., Elhay M.J., Silva R., Appelberg R., and Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. Immun. 65 (1997) 623-629
2. Nasser Eddine A., and Kaufmann S.H.E. Improved protection by recombinant BCG. Microbes. Infect. 7 (2005) 939-946
3. Rook G.A.W., Dheda K., and Zumla A. Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat. Rev. Immunol. 5 (2005) 661-667
4. Dietrich G., Viret J.F., and Hess J. Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments. Vaccine 21 (2003) 667-670
5. De Magistris M.T. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv. Drug. Deliv. Rev. 58 (2006) 52-67
6. Payne L.G., Jenkins S.A., Anderianov A., and Robert B.E. Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. In: Powel M.F., and Newman M.J. (Eds). Vaccine Design: The Subunit and Adjuvant Approach (1995), Plenum Press, New York 473-493
7. Gazzinelli R.T., Ropert C., Almeida I.C., Silva J.S., and Campos M.A. Glycosylphosphatidylinositol anchors as natural immunological adjuvants derived from protozoan parasites. In: Hackett C.J., and Harn D.A. (Eds). Vaccine Adjuvants (2006), Humana Press, New Jersey 155-175
8. Andersen P., and Doherty T.M. TB subunit vaccines-putting the pieces together. Microbes. Infect. 7 (2005) 911-921
9. Kulseng B., Skjak-Braek G., Ryan L., Andersson A., King A., Faxvaag A., et al. Transplantation of alginate microcapsules: generation of antibodies against alginates and encapsulated porcine islet-like cell clusters. Transplantation 67 (1999) 978-984
10. Patel G. Sodium alginate, a natural polysaccharide has the stability, solubility, viscosity and safety needed in a pharmaceutical excipient. Available from:. (accessed 18.03.06)
11. Aguilar J.C., and Rodriguez E.G. Vaccine adjuvants revised. Vaccine 25 (2007) 3752-3762
12. McShane H. Developing an improved vaccine against tuberculosis. Expert Rev. Vaccines 3 (2004) 299-306
13. Andersen P., Andersen A.B., Sorensen A.L., and Nagai S. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J. Immunol. 154 (1995) 3359-3372
14. Lagranderie M., Balazuc A.M., Deriaud E., Leclere C.D., and Gheorghiu M. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect. Immun. 64 (1996) 1-9
15. Haile M., Schroder U., Hamasur B., Pawlowski A., Jaxmar T., Kallenius G., et al. Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis. Vaccine 22 (2004) 1498-1508
16. Williams A., Davies A., Marsh Ph.D., Chambers M.A., and Hewinson R.G. Comparison of the protective efficacy of Bacille Calmette-Guerin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis. Clin. Infect. Dis. 30 (2000) S229-S301
17. Ajdary S., Dobakhti F., Taghikhani M., Riazi-Rad F., Rafiei S., and Rafiee-Tehrani M. Oral administration of Mycobacterium bovis BCG encapsulated in alginate microspheres induces protective immunity in BALB/c mice. Vaccine 25 (2007) 4595-4601
18. Brewer J.M., and Pollock K.G.J. Adjuvant-induced Th2- and Th1- dominated immune responses in vaccination. In: Kaufmann S.H.E. (Ed). Novel Vaccination Strategies (2004), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 51-72
19. Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5 (2007) 505-517
20. Mackay I.R., and Rosen F.S. Advances in immunology. N. Engl. J. Med. 345 (2001) 1042-1053
21. Cox E., Verdonck F., Vanrompay D., and Goddeeris B. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet. Res. 37 (2006) 511-539
22. Mescher M.F., Curtsinger J.M., and Jenkins M. Adjuvants and the initiation of T-cell responses. In: Hackett C.J., and Harn D.A. (Eds). Vaccine Adjuvants (2006), Humana Press, New Jersey 49-67